Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer

Breast Cancer

Volumn 11, Issue 1, 2004, Pages 38-41

  Kurebayashi, Junichi ^a   Okubo, Sumiko ^a   Yamamoto, Yutaka ^a   Sonoo, Hiroshi ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Antiestrogen; Breast cancer; Endocrine therapy; HER1; Tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR; ESTRADIOL; FULVESTRANT; GEFITINIB; QUINAZOLINE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BREAST TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG SYNERGISM; EPIDERMAL GROWTH FACTOR; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENE EXPRESSION REGULATION; GENES, ERBB-1; HUMANS; QUINAZOLINES; SIGNAL TRANSDUCTION;

EID: 1542320044     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02968000     Document Type: Article

References (23)

1. Kurebayashi J: Biological and clinical significance of HER2 overexpression in breast cancer. Breast Cancer 8:45-51, 2001.
2. Yarden Y, Sliwkowski MX: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2:127-137, 2001.
3. Arteaga CL: Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 5 (Suppl 14) :3-9, 2002. (Pubitemid 35191041)
4. Kurebayashi J: Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance. Breast Cancer 10:112-119, 2003.
5. Nicholson S, Sainsbury JR, Halcrow P, Chambers P, Farndon JR, Harris AL: Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet i (8631):182-185, 1989. (Pubitemid 19038803)
6. van Agthoven T, van Agthoven TL, Portengen H, Foekens JA, Dorssers LC: Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res 52:5082-5088, 1992.
7. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494, 1995.
8. Bunone G, Briand PA, Miksicek RJ, Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 15:2174-2183, 1996. (Pubitemid 26141134)
9. Chen D, Riedl T, Washbrook E, Pace PE, Coombes RC, Egly JM, Ali S: Activation of estrogen receptor alpha by S118 phosphorylation involves a liganddependent interaction with TFIIH and participation of CDK7. Mol Cell 6:127-137, 2000.
10. Kurokawa H, Arteaga CL: Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin Cancer Res 7 (12 Suppl):4436s-4442s, 2001. (Pubitemid 34031593)
11. Martin MB, Franke TF, Stoica GE, Chambon P, Katzenellenbogen BS, Stoica BA, McLemore MS, Olivo SE, Stoica A: A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 141:4503-4511, 2000. (Pubitemid 32055127)
12. Campbell RA, Bhat-Nakshatri P, Patel NM, Constanfinidou D, Ali S, Nakshatri H: Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276:9817-9824, 2001.
13. Ritter CA, Arteaga CL: The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 30 (1 Suppl 1):3-11, 2003. (Pubitemid 36307612)
14. Yamamoto Y: Prognostic and predictive values of HER1 and HER,? overexpression in breast cancer. Kawasaki Igakkaishi 29:47-58, 2003.
15. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61:8887-8895, 2001. (Pubitemid 34013905)
16. Morris C: The role of EGFR-directed therapy in the treatment of breast cancer. Breast Cancer Res Treat 75 (Suppl 1):S51-S55, 2002. (Pubitemid 35015090)
17. Kurebayashi J, Okubo S, Yamamoto Y, Otsuki T, Sonoo H: The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ('Iressa') enhances the antitumor effect of the antiestrogen ICI 182,780 ('Faslodex') in estrogen-receptor-positive breast cancer cells. Breast Cancer Res Treat 76 (Suppl 1):S71, 2002.
18. Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE, Dowsett M: Integration of signal transducfion inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin Cancer Res 9:524S-532S, 2003. (Pubitemid 36105797)
19. Arteaga CL: Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7 (Suppl 4):31-39, 2002. (Pubitemid 34977161)
20. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Onco1 20:4292-4302, 2002. (Pubitemid 35266289)
21. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Onco1 20:3815-3825, 2002.
22. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H, Rowinsky EK: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase T trial. J Clin Onco1 20:2240-2250, 2002. (Pubitemid 34441651)
23. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T: Severe acute interstitial pneumonia and gefitinib. Lancet 361 (9352):137-139, 2003. (Pubitemid 36092019)